News
03-24-2011, 03:12 AM
Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.
More... (http://www.news-medical.net/news/20110324/Prolia-associated-with-greater-adherence-than-alendronate-in-postmenopausal-women-with-osteoporosis.aspx)
More... (http://www.news-medical.net/news/20110324/Prolia-associated-with-greater-adherence-than-alendronate-in-postmenopausal-women-with-osteoporosis.aspx)